Accéder au contenu
Merck

Elastin development-associated extracellular matrix constituents of subepithelial connective tissue in human pterygium.

Investigative ophthalmology & visual science (2014-09-04)
Consuelo Pérez-Rico, Gemma Pascual, Sandra Sotomayor, Ángel Asúnsolo, Alberto Cifuentes, Natalio García-Honduvilla, Julia Buján
RÉSUMÉ

We evaluated the expression of several extracellular matrix constituents implicated in the synthesis and reticulation of elastin in human pterygium, according to age and sex of the patients. Pterygia and normal conjunctiva samples were divided into groups according to age (<50/≥50 years) and sex. Tissue was subjected to immunohistochemical staining with anti-lysyl oxidase (LOX), lyxyl oxidase-like 1 (LOXL-1), fibulin (FBLN)-5 and FBLN4, and fibrillin-1 (FBN1) antibodies. Specific primers for the same constituents were used in a quantitative real-time PCR (qRT-PCR) analysis to determine gene expression. The LOXL-1 (P = 0.0002), FBLN5 (P = 0.0035), and FBN1 (P < 0.0001) mRNAs were significantly higher in pterygium than conjunctiva. No differences were found for LOX and FBLN4 mRNA. The expression of LOXL-1 was not affected by age or sex; however, pterygium from men and patients over 50 years old exhibited significantly higher FBLN5/FBN1 expression than did controls. The LOX gene expression was higher in the pathologic samples from the over 50-year-olds compared to the conjunctiva (P = 0.0396) and in men's versus women's pterygium (P = 0.0173). In general, the levels of LOX, LOXL-1, and FBLN5 decreased with age in healthy samples, while the pathology seemed to have increased expression of the three proteins, and even more so in older patients. The FBLN4 and FBN1 immunostaining was slight in all samples, displaying no differences between groups. Several extracellular matrix constituents, LOXs, FBN1, and FBLN5, implicated in the development of elastin, are overexpressed in the subepithelial connective tissue extracellular matrix of human pterygium, supporting our hypothesis that elastic synthesis and reticulation is dysregulated in this type of pathology.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard